Abstract
Traumatic brain injury (TBI) is an important public health concern plagued by high rates of mortality and significant long-term disability in many survivors. Post-traumatic seizures (PTS) are not uncommon following TBI, both in the early (within 7 days post-injury) and late (after 7 days post-injury) period. Due to the potential of PTS to exacerbate secondary injury following TBI and the possibility of developing post-traumatic epilepsy (PTE), the medical community has explored preventative treatment strategies. Prophylactic antiepileptic drug (AED) administration has been proposed as a measure to reduce the incidence of PTS and the ultimate development of PTE in TBI patients. In this topical review, we discuss the pathophysiologic mechanisms of early and late PTS and the development of PTE following TBI, the pharmacodynamic and pharmacokinetic properties of AEDs commonly used to prevent post-traumatic seizures, and summarize the available clinical evidence for employing AEDs for seizure prophylaxis after TBI.
Keywords: Antiepileptic drugs, post-traumatic seizure, prophylaxis, traumatic brain injury, post-traumatic epilepsy (PTE), antiepileptic drug (AED).
Current Pharmaceutical Design
Title:Antiepileptics for Post-Traumatic Seizure Prophylaxis after Traumatic Brain Injury
Volume: 23 Issue: 42
Author(s): Alexander G. Chartrain, Kurt Yaeger, Rui Feng, Marios S. Themistocleous, Neha S. Dangayach, Konstantinos Margetis and Zachary L. Hickman*
Affiliation:
- Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY,United States
Keywords: Antiepileptic drugs, post-traumatic seizure, prophylaxis, traumatic brain injury, post-traumatic epilepsy (PTE), antiepileptic drug (AED).
Abstract: Traumatic brain injury (TBI) is an important public health concern plagued by high rates of mortality and significant long-term disability in many survivors. Post-traumatic seizures (PTS) are not uncommon following TBI, both in the early (within 7 days post-injury) and late (after 7 days post-injury) period. Due to the potential of PTS to exacerbate secondary injury following TBI and the possibility of developing post-traumatic epilepsy (PTE), the medical community has explored preventative treatment strategies. Prophylactic antiepileptic drug (AED) administration has been proposed as a measure to reduce the incidence of PTS and the ultimate development of PTE in TBI patients. In this topical review, we discuss the pathophysiologic mechanisms of early and late PTS and the development of PTE following TBI, the pharmacodynamic and pharmacokinetic properties of AEDs commonly used to prevent post-traumatic seizures, and summarize the available clinical evidence for employing AEDs for seizure prophylaxis after TBI.
Export Options
About this article
Cite this article as:
Chartrain G. Alexander, Yaeger Kurt , Feng Rui, Themistocleous S. Marios, Dangayach S. Neha , Margetis Konstantinos and Hickman L. Zachary*, Antiepileptics for Post-Traumatic Seizure Prophylaxis after Traumatic Brain Injury, Current Pharmaceutical Design 2017; 23 (42) . https://dx.doi.org/10.2174/1381612823666171031100139
DOI https://dx.doi.org/10.2174/1381612823666171031100139 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Genetic Dissection of Antipsychotic Induced Movement Disorders
Current Medicinal Chemistry Anticonvulsant and Antinociceptive Actions of Novel Adenosine Kinase Inhibitors
Current Topics in Medicinal Chemistry Automated Radiosynthesis and Molecular Docking Studies of Coumarin- Triazole Hybrid with fluorine-18: A feasibility study
Current Radiopharmaceuticals A Very Rare Cerebral Complication of Chemotherapy in a Young Girl: A Difficult Diagnosis
Current Drug Safety Voltage Gated ion Channels: Targets for Anticonvulsant Drugs
Current Topics in Medicinal Chemistry Mitochondrial Complex I Deficiency in Humans
Current Genomics Benzothiazoles - Scaffold of Interest for CNS Targeted Drugs
Current Medicinal Chemistry HCN Channel as Therapeutic Targets for Heart Failure and Pain
Current Topics in Medicinal Chemistry Development and Validation of a Fluorescence-Based HTS Assay for the Identification of P/Q-Type Calcium Channel Blockers
Combinatorial Chemistry & High Throughput Screening Glycaemic Control: A Balancing Act or A Different Approach?
Current Diabetes Reviews Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism Recent Progress in Research on Ribosome Inactivating Proteins
Current Protein & Peptide Science Simple and Fast Gas-chromatography Mass Spectrometry Assay to Assess Delta 9-Tetrahydrocannabinol and Cannabidiol in Dogs Treated with Medical Cannabis for Canine Epilepsy
Current Pharmaceutical Biotechnology New Anticonvulsant Agents
Current Topics in Medicinal Chemistry Therapeutic Potential of Voltage Gated Calcium Channels
Mini-Reviews in Medicinal Chemistry Relationship Between the Chemokine Receptor CCR5 and Microglia in Neurological Disorders: Consequences of Targeting CCR5 on Neuroinflammation, Neuronal Death and Regeneration in a Model of Epilepsy
CNS & Neurological Disorders - Drug Targets Pharmacogenetics of Obesity Drug Therapy
Current Molecular Medicine Carvacrol as a Potential Neuroprotective Agent for Neurological Diseases: A Systematic Review Article
CNS & Neurological Disorders - Drug Targets Computational Methods in Determination of Pharmacophore Models of 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub> and 5-HT<sub>7</sub> Receptors
Mini-Reviews in Medicinal Chemistry Genes Involved in Hereditary Hearing Impairment
Current Genomics